MIR-16 mediates trastuzumab and lapatinib response in ERBB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Venturutti L , Cordo Russo RI, Rivas MA, Mercogliano MF, Izzo F, Oakley RH, Pereyra MG, De Martino M, Proietti CJ, Yankilevich P, Roa JC , Guzman P, Cortese E, Allemand DH, Huang TH, Charreau EH, Cidlowski JA, Schillaci R, Elizalde PV .